N/A N=10 Basic Science

Clinical Evidence of pH Dependent ß2 Adrenergic Transport Mechanisms in the Airway

Healthy Volunteers

Bottom Line

View on ClinicalTrials.gov: NCT01216748 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Dec 2014

Primary outcome: Primary: Changes in Airway Blood Flow After 180μg Albuterol by Inhalation (ΔQaw) vs Baseline — 16.8; 14.5; -0.2; 2.0 changes from baseline in μl.min-1.ml-1

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: quiet breathing (Other); Hypocapnic Hyperventilation (Other); Hypercapnic Hyperventilation (Other); eucapnic hyperventilation (Other)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Miami
Primary completion: Jul 2010

Outcome Measures

Outcome	Result	p-value
PRIMARY Changes in Airway Blood Flow After 180μg Albuterol by Inhalation (ΔQaw) vs Baseline	16.8; 14.5; -0.2; 2.0	—
SECONDARY Exhaled Breath Condensate (EBC) pH Variation	6.39; 6.31; 6.59; 5.88	—

Summary

The purpose of this study was to determine if airway pH has an effect on albuterol-induced vasodilation in the airway. Methods: Ten healthy volunteers performed the following respiratory maneuvers: quiet breathing, hypocapnic hyperventilation, hypercapnic hyperventilation, and eucapnic hyperventilation

Eligibility Criteria

Inclusion Criteria

Lifetime non-smokers
FEV1 > 80% predicted value and FEV1/FVC > 0.75

Exclusion Criteria

Cardiovascular disease or use of cardiovascular or vasoactive drugs;
Lung disease or use of airway drugs (i.e. inhaled corticosteroids, β adrenergic agonists);
Respiratory infection during the 4 weeks preceding the study
Use of systemic glucocorticoids within 4 weeks of the study
Pregnant or nursing females

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01216748). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.